Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU's "Horizon 2020" to fund innovative drug/diagnostic R&D and boost life sciences industry

This article was originally published in Scrip

Executive Summary

The European Parliament has given the go-ahead to "Horizon 2020", the EU's most ambitious research and innovation program to date. With a budget of almost €80bn over seven years, the program includes public-private partnerships in areas such as novel medicines, biomarkers and diagnostics.

You may also be interested in...



REPAIR Is Trying To Fix The Antibiotic Gap Left By Industry

As large biopharmaceutical companies continue to exit antibacterial R&D, investments by Novo Holding’s REPAIR Impact Fund and grants from CARB-X can push forward novel therapies for drug-resistant microbial infections.

EU Bodies Back Mix-And-Match Approach For COVID-19 Boosters

New advice on the use of "mix-and-match" primary and booster vaccine regimens has been published by the EMA and the ECDC, while a new CEPI-supported clinical trial will test heterologous booster combinations involving Medigen’s COVID-19 vaccine and other jabs.

Coronavirus Notebook: EMA OKs Roche's Tocilizumab For Severe COVID-19, Bavarian Nordic Reports ‘Positive’ Booster Results

The European Commission is to replace its COVID-19 vaccine export authorization system with a monitoring scheme, and the European Medicines Agency has confirmed the risk of myocarditis and pericarditis with the mRNA vaccines. The WHO and other bodies have called for better vaccine donation practices in Africa.

Topics

UsernamePublicRestriction

Register

SC023557

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel